Effect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre
Indian Journal of Endocrinology and Metabolism · 2026-03 · 30 (2) · 157-163
DOI: 10.4103/ijem.ijem_1075_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Endocrinology and Metabolism, online erschienen am 30.04.2026. Verfasst von Bandana Dash und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Introduction
Metabolic dysfunction-associated steatotic liver disease (MASLD) is highly prevalent in individuals with type 2 diabetes mellitus (T2DM). This study evaluated the effect of dapagliflozin on liver fat, liver stiffness, and visceral adiposity in patients with T2DM and MASLD.
Methods
This was a single-arm, prospective, open-label interventional study with a paired design. Sixty-three patients with T2DM and moderate-to-severe hepatic steatosis on ultrasonography received dapagliflozin 10 mg daily for six months. Liver fat by dual-echo-magnetic resonance imaging (MRI), liver stiffness measurement (LSM) by fibroscan, and visceral adipose tissue (VAT) by dual X-ray absorptiometry were assessed at baseline and after six months. Response to therapy was defined as >10% decrease in liver fat and >15% decrease in LSM, respectively (Responders). Multivariable logistic regression analysis was performed to identify predictors of response with respect to change in liver fat and LSM.
Results
After six months, mean weight decreased by 2.55 kg (3.23%) and HbA1c by 0.84%. MRI-liver fat percentage, LSM, and VAT volume declined by 2.7%, 0.85kPa, and 472 cm 3 , respectively ( P < 0.001 for all). Change in VAT mass ( r = 0.546) and volume ( r = 0.437) correlated with change in liver fat, and change in aspartate aminotransferase (AST) correlated with change in LSM ( r = 0.351). Sixteen patients (25.4%) and 33 patients (52.4%) met the criteria for responders for liver fat and LSM, respectively. Baseline liver fat and LSM were independent predictors of decrease in liver fat and LSM, respectively in responders.
Conclusion
Dapagliflozin significantly reduced liver fat, liver stiffness, and visceral adiposity in patients with T2DM and MASLD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, M.K.C.G Medical College, Berhampur, Odisha, India.
- Department of Radiology, M.K.C.G Medical College, Berhampur, Odisha, India.
Zitieren
APA
Dash, B., Ravi Kumar, P., Dash, D. K., Patro, D., Sahu, P. K., & Rao, M. V. K. (2026). Effect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre. Indian Journal of Endocrinology and Metabolism, 30(2), 157-163. https://doi.org/10.4103/ijem.ijem_1075_25
Vancouver
Dash B, Ravi Kumar P, Dash DK, Patro D, Sahu PK, Rao MVK. Effect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre. Indian Journal of Endocrinology and Metabolism. 2026;30(2):157-163. doi:10.4103/ijem.ijem_1075_25
BibTeX
@article{Dash2026,
author = {Dash, Bandana and Ravi Kumar, Padala and Dash, Deepak K and Patro, Debasish and Sahu, Pradosh K and Rao, Mandapaka V K},
title = {Effect of Dapagliflozin on Liver Fat, Liver Stiffness, and Visceral Adiposity in Patients with Type 2 Diabetes Mellitus and MASLD: An Open-Label Study from a Tertiary Care Centre},
journal = {Indian Journal of Endocrinology and Metabolism},
year = {2026},
volume = {30},
number = {2},
pages = {157--163},
doi = {10.4103/ijem.ijem_1075_25}
}
EUVIMED